Business Context and Reporting Period
Company: James Hardie Industries plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2018 (Specifically dated February 6, 2018)
Principal Executive Offices: Dublin 2, Ireland
This filing serves as a report of a specific corporate governance event rather than a financial results announcement. The primary purpose is to disclose the appointment of a Non-Executive Director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding board composition and does not contain financial statements or operational data for the period.
Material Changes
- Board Composition: Appointment of a Non-Executive Director effective February 5, 2018 (Exhibit 99.1).
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes an extensive disclaimer regarding forward-looking statements. These statements cover future performance, capital expenditure, credit facilities, dividends, tax liabilities, and legal proceedings.
Key Risks Disclosed:
- Asbestos Liability: Risks related to prior asbestos manufacturing, including contributions to the Asbestos Injuries Compensation Fund (AICF) and potential shortfalls.
- Legal and Regulatory: Exposure to product liability, environmental, and consumer class action proceedings.
- Economic Conditions: Dependence on US and Asia Pacific housing markets, new home construction, and renovation levels.
- Operational: Supply and cost of raw materials, currency exchange risks, and the integration of the Fermacell acquisition.
- Financial: Ability to renew credit facilities and manage warranty provisions.
Management Commentary: No specific management commentary on current operations or future guidance is provided in this text, other than the standard caution that actual results may differ materially from projections.
Investor Verification Checklist
- Verify the identity and background of the newly appointed Non-Executive Director referenced in Exhibit 99.1.
- Review the most recent Form 20-F (filed May 18, 2017) for detailed financial metrics and risk factors referenced in this filing.
- Monitor updates regarding the Asbestos Injuries Compensation Fund (AICF) contributions and any changes to the governmental loan facility.
- Track the integration progress and financial impact of the Fermacell acquisition.